Achiko AG Production and Sales Update
AptameX™ Gen 2 Covid-19 rapid calibration outperforms Abbott Pan Bio and Clugene’s rapid tests in Indonesia in validation tests.Sample of 20 PCR Positive and 9 Negative samples, indicated a 100% m...
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. The company's lead product is AptameX, a rapid test that uses DNA aptamers instead of antigens to detect the SARS-CoV-2 virus. It also offers Teman Sehat, a mobile check-in and passport application. In addition, the company provides secure payment solutions for game publishers and application developers to accept various payment methods for digital contents and goods under the Mimopay brand, as well as develops game software. Achiko AG was incorporated in 2018 and is headquartered in Zurich, Switzerland.
0.0026 | |
0.0026 | |
- | |
0.0026 | |
0.0026 | |
0.0026-0.0036 | |
377 K | |
145 M | |
24 596 | |
-0.0388 | |
-0.393 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
AptameX™ Gen 2 Covid-19 rapid calibration outperforms Abbott Pan Bio and Clugene’s rapid tests in Indonesia in validation tests.Sample of 20 PCR Positive and 9 Negative samples, indicated a 100% m...
ZURICH, Switzerland, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) held its Annual General Meeting today at 10:00 CET in ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: